ANZGOG’s endometrial cancer study AtTEnd closes to recruitment
The AtTEnd clinical trial is for women with advanced stage or recurrent endometrial cancer and will assess whether the use of the immune therapy atezolizumab is of additional benefit to current, first line chemotherapy combination. [...]















